Showing results (291-300 of 313) with videos related to
Sort By:
Pageof 32
Public Health Genomics|April 17, 2010
Framing genomics, public health research and policy: points to considerBartha Maria Knoppers, T Leroux, H Doucet, et al.ESMO Open|August 7, 2026
Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohortE Gobbini, M H Diallo, C Clément-Duchene, et al.Nature Communications|April 16, 2015
Twisting phonons in complex crystals with quasi-one-dimensional substructuresXi Chen, Annie Weathers, Jesús Carrete, et al.ESMO Open|June 7, 2023
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trialN Girard, S Ponce Aix, S Cedres, et al.Journal of Child Neurology|June 1, 2000
Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlationF Bernaudin, S Verlhac, F Fréard, et al.ESMO Open|November 28, 2024
Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN studyN Girard, F Guisier, A Swalduz, et al.Journal of Bone Oncology|June 21, 2021
Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinomaE Massy, J C Rousseau, M Gueye, et al.ESMO Open|July 24, 2025
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysisK Amrane, B Cabarrou, G Justeau, et al.ESMO Open|December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancerO Molinier, B Besse, F Barlesi, et al.ESMO Open|June 4, 2024
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohortQ D Thomas, X Quantin, P Lemercier, et al.Pageof 32